Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib or placebo plus chemotherapy for perioperative treatment of resectable EGFR-mutant non-small cell lung cancer
CTR20201857Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Hengrui Therapeutics. Started Sep 2020; status: active.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20201857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201857.